Body mass index in non-small cell lung cancer patients treated with anti-PD-1 immune checkpoint inhibitors.

Journal of global oncology Pub Date : 2019-10-07 DOI:10.1200/jgo.2019.5.suppl.68

A. Tateishi, H. Horinouchi, K. Masuda, H. Jo, Y. Shinno, Y. Okuma, T. Yoshida, Y. Goto, N. Yamamoto, Y. Ohe

{"title":"Body mass index in non-small cell lung cancer patients treated with anti-PD-1 immune checkpoint inhibitors.","authors":"A. Tateishi, H. Horinouchi, K. Masuda, H. Jo, Y. Shinno, Y. Okuma, T. Yoshida, Y. Goto, N. Yamamoto, Y. Ohe","doi":"10.1200/jgo.2019.5.suppl.68","DOIUrl":null,"url":null,"abstract":"68 Background: Previous retrospective analyses have revealed higher response rates and a trend towards longer progression-free survival (PFS) and overall survival (OS) in response to immune checkpoint inhibitors (ICIs) in overweight patients. There are few reports concerning the association between the overweight state and the efficacy of ICIs specifically in non-small cell lung cancer (NSCLC) patients. We investigated the association between the body mass index (BMI) and the efficacy of ICIs in patients with NSCLC. Methods: Patients with advanced NSCLC who received ICI therapy (nivolumab or pembrolizumab) at the National Cancer Center Hospital from January 2016 to December 2018 were included in this retrospective cohort study. Based on their BMI, the patients were categorized into the overweight (A) group (BMI ≥25) and the non-overweight (B) group (BMI < 25). The PFS was compared between the two groups as the primary outcome. Results: Data of a total of 323 patients (median age, 63 years) were analyzed; 87 (26.9%)/43 (13.3%)/193 (59.8%) patients received pembrolizumab as 1st line therapy, pembrolizumab as 2nd line therapy, and nivolumab, respectively. Tumor proportion score was ≥50% in 58.4% (139/238) patients. The ECOG-PS was ≥2 in 37 patients (11.5%). The median body weight was 58.1, and the median BMI was 21.4. Of the 323 patients, 46 (14.2%) were categorized into group A (overweight) and 277 (85.8%) into group B (non-overweight). The median PFS and OS in two groups were as follows: A, 6.9 m/B, 5.6 m (HR 0.84, 95% CI [0.57-1.25], p = 0.38), and A, 22.3 m/B, 15.4 m (HR 0.90, 95% CI [0.56-1.43], p = 0.64), respectively. In accordance with the ICI regimen that the patients received, the PFS was A, 7.9 m/B, 7.8 m (HR 0.86, 95%CI [0.37-2.04], p = 0.74) in the patients who received pembrolizumab as 1st line therapy, A, 7.5 m/B, 5.3 m (HR 0.60, 95% CI [0.18-2.00], p = 0.40) in the patients who received pembrolizumab as 2nd line therapy, and A, 6.5 m/B, 4.4 m (HR 0.84, 95% CI [0.52-1.36], p = 0.48) in the patients who received nivolumab. Conclusions: Overweight NSCLC patients treated with ICIs showed a trend (non-statistically significant) towards a longer PFS as compared to non-overweight patients.","PeriodicalId":15862,"journal":{"name":"Journal of global oncology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of global oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/jgo.2019.5.suppl.68","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

68 Background: Previous retrospective analyses have revealed higher response rates and a trend towards longer progression-free survival (PFS) and overall survival (OS) in response to immune checkpoint inhibitors (ICIs) in overweight patients. There are few reports concerning the association between the overweight state and the efficacy of ICIs specifically in non-small cell lung cancer (NSCLC) patients. We investigated the association between the body mass index (BMI) and the efficacy of ICIs in patients with NSCLC. Methods: Patients with advanced NSCLC who received ICI therapy (nivolumab or pembrolizumab) at the National Cancer Center Hospital from January 2016 to December 2018 were included in this retrospective cohort study. Based on their BMI, the patients were categorized into the overweight (A) group (BMI ≥25) and the non-overweight (B) group (BMI < 25). The PFS was compared between the two groups as the primary outcome. Results: Data of a total of 323 patients (median age, 63 years) were analyzed; 87 (26.9%)/43 (13.3%)/193 (59.8%) patients received pembrolizumab as 1st line therapy, pembrolizumab as 2nd line therapy, and nivolumab, respectively. Tumor proportion score was ≥50% in 58.4% (139/238) patients. The ECOG-PS was ≥2 in 37 patients (11.5%). The median body weight was 58.1, and the median BMI was 21.4. Of the 323 patients, 46 (14.2%) were categorized into group A (overweight) and 277 (85.8%) into group B (non-overweight). The median PFS and OS in two groups were as follows: A, 6.9 m/B, 5.6 m (HR 0.84, 95% CI [0.57-1.25], p = 0.38), and A, 22.3 m/B, 15.4 m (HR 0.90, 95% CI [0.56-1.43], p = 0.64), respectively. In accordance with the ICI regimen that the patients received, the PFS was A, 7.9 m/B, 7.8 m (HR 0.86, 95%CI [0.37-2.04], p = 0.74) in the patients who received pembrolizumab as 1st line therapy, A, 7.5 m/B, 5.3 m (HR 0.60, 95% CI [0.18-2.00], p = 0.40) in the patients who received pembrolizumab as 2nd line therapy, and A, 6.5 m/B, 4.4 m (HR 0.84, 95% CI [0.52-1.36], p = 0.48) in the patients who received nivolumab. Conclusions: Overweight NSCLC patients treated with ICIs showed a trend (non-statistically significant) towards a longer PFS as compared to non-overweight patients.

查看原文本刊更多论文

抗pd -1免疫检查点抑制剂治疗的非小细胞肺癌患者的体重指数

68背景:以往的回顾性分析显示，超重患者对免疫检查点抑制剂(ICIs)的应答率更高，无进展生存期(PFS)和总生存期(OS)更长。关于非小细胞肺癌(NSCLC)患者超重状态与ICIs疗效之间关系的报道很少。我们研究了非小细胞肺癌患者的身体质量指数(BMI)与ICIs疗效之间的关系。方法:2016年1月至2018年12月在国家癌症中心医院接受ICI治疗(纳武单抗或派姆单抗)的晚期NSCLC患者纳入本回顾性队列研究。根据BMI将患者分为超重(A)组(BMI≥25)和非超重(B)组(BMI < 25)。将两组间的PFS作为主要终点进行比较。结果:共分析323例患者资料，中位年龄63岁;分别有87例(26.9%)/43例(13.3%)/193例(59.8%)患者接受了派姆单抗作为一线治疗、派姆单抗作为二线治疗和纳武单抗。58.4%(139/238)患者肿瘤比例评分≥50%。ECOG-PS≥2者37例(11.5%)。中位体重为58.1，中位BMI为21.4。323例患者中，A组(超重)46例(14.2%)，B组(非超重)277例(85.8%)。两组患者的中位PFS和OS分别为:A, 6.9 m/B, 5.6 m (HR 0.84, 95% CI [0.57-1.25]， p = 0.38)， A, 22.3 m/B, 15.4 m (HR 0.90, 95% CI [0.56-1.43]， p = 0.64)。根据患者所接受的ICI方案，接受派姆单抗一线治疗的患者PFS分别为A、7.9 m/B、7.8 m (HR 0.86, 95%CI [0.37-2.04]， p = 0.74)，接受派姆单抗二线治疗的患者PFS分别为A、7.5 m/B、5.3 m (HR 0.60, 95%CI [0.18-2.00]， p = 0.40)，接受纳武单抗的患者PFS分别为A、6.5 m/B、4.4 m (HR 0.84, 95%CI [0.52-1.36]， p = 0.48)。结论:与非超重患者相比，接受ICIs治疗的超重NSCLC患者有更长的PFS趋势(无统计学意义)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of global oncology ONCOLOGY-

自引率

0.00%

发文量

审稿时长

20 weeks

期刊介绍： The Journal of Global Oncology (JGO) is an online only, open access journal focused on cancer care, research and care delivery issues unique to countries and settings with limited healthcare resources. JGO aims to provide a home for high-quality literature that fulfills a growing need for content describing the array of challenges health care professionals in resource-constrained settings face. Article types include original reports, review articles, commentaries, correspondence/replies, special articles and editorials.